Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

WHO Updates Cervical Cancer Guidelines to Incorporate Roche’s Dual-Stain Test

NextEdge Admin

24 Sep 2024

2 min 20 sec

The World Health Organization (WHO) has updated its cervical cancer prevention guidelines to include Roche’s CINtec PLUS Cytology test, a dual-stain cytology test for individuals at high risk of developing cervical precancer and cancer. This test, which detects the biomarkers p16 and Ki-67 within the same cell, helps identify potential cellular transformation into cancer.

A positive dual-stain result indicates a higher risk of cervical cancer, prompting immediate colposcopy, while a negative result suggests low risk, allowing for retesting later. The test uses the same liquid sample collected for HPV or Pap cytology tests, eliminating the need for additional samples.

Roche’s CINtec PLUS Cytology test, already approved by the FDA and CE-marked, provides valuable information for clinicians, patients, and laboratories, helping reduce unnecessary follow-up visits and associated costs. The recent WHO endorsement follows an earlier update by the American Society for Colposcopy and Cervical Pathology (ASCCP), which also included dual-stain cytology as a triage test for HPV-positive individuals.

Roche Diagnostics CEO, Matt Sause, highlighted the importance of the test in identifying those at elevated risk for cervical cancer, noting that HPV infections are a leading cause of this highly preventable disease. This WHO guideline update further strengthens Roche’s portfolio, which includes its cobas HPV test on various platforms for both clinician-collected and self-collected samples.

This update marks another step forward in cervical cancer prevention, allowing for more accurate risk assessment and improved patient management.